| Document |
Document Title |
|
WO/2015/082046A2 |
The invention relates to materials, to electroluminescence devices comprising said materials and to the use thereof.
|
|
WO/2015/079009A1 |
The present invention provides new therapeutic compounds for treatment of diseases caused or influenced by microtubule stability, such as proliferative diseases. The compounds are phenyl-analogs of the naturally occurring peloruside. The...
|
|
WO/2015/067657A1 |
A process for the oxidation of an organic carbonyl compound comprising reacting the compound, optionally in the presence of a solvent, with hydrogen peroxide in the presence of a catalyst comprising a tin-containing zeolitic material and...
|
|
WO/2015/067654A1 |
A process for preparing a tin-containing zeolitic material having a BEA framework structure comprising providing a zeolitic material having a BEA framework structure having vacant tetrahedral framework sites, providing a tin-ion source i...
|
|
WO/2015/063579A1 |
The present invention refers to a new "one-pot" process for the preparation of olopatadine via intermediates of formula (III).
|
|
WO/2015/033261A1 |
The present application provides a catalytic process which involves the cyclization of a novel catalytic intramolecular arylation process that involves boronic acid or ester aldehydes or imines substrates, of formula (I) and (II), to aff...
|
|
WO/2014/188762A1 |
The present invention is a radiation-sensitive resin composition which contains a polymer having a structural unit that contains an acid-cleavable group and a compound represented by formula (1). In formula (1), R1 represents a monovalen...
|
|
WO/2014/180556A1 |
The present invention relates to arylpiperazines, and to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in P...
|
|
WO/2014/147647A1 |
The present invention provides a process for the synthesis of olopatadine. Further, the invention discloses a process that results in improved yield of the desired Z isomer.
|
|
WO/2014/138823A1 |
The present disclosure relates to compounds of formula I in the treatment and/or prevention of a Gram-negative bacterial infection in a multicellular organism. The disclosure also relates to a pharmaceutical composition comprising said c...
|
|
WO/2014/133361A1 |
The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereo...
|
|
WO/2014/122294A1 |
The invention relates to a process for preparing a cyclic ester or a cyclic amide, comprising the step of: contacting at least one hydroxycarboxylic acid and/or at least one amino-carboxylic acid; or an ester, or salt thereof; wherein sa...
|
|
WO/2014/118740A1 |
The present invention provides compounds represented by Formula 1: wherein, R' is as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable...
|
|
WO/2014/048692A1 |
The present invention relates to a method for producing metathesis products comprising contacting metathesis starting materials under metathesis conditions with a metathesis catalyst, wherein the metathesis catalyst is employed in an amo...
|
|
WO/2014/040636A1 |
The present invention relates primarily to compounds of the formula (Ia) or (Ib) (as described herein), to mixtures comprising or consisting of compounds of the formula (Ia) or (Ib), and to perfumed products comprising a (preferably sens...
|
|
WO/2014/037964A2 |
The present invention discloses organocatalytic process for asymmetric synthesis of highly enantioselective decanolide compounds in high yield with > 99% ee. Further, the present invention disclose cost effective, improved organocatalyti...
|
|
WO/2014/034190A1 |
The present invention is a radiation-sensitive resin composition, which contains an acid-cleavable group-containing polymer, a radiation-sensitive acid generator and a solvent, and wherein the radiation-sensitive acid generator contains ...
|
|
WO/2014/018765A1 |
The invention provides compounds useful as anti-cancer agents.
|
|
WO/2013/190481A1 |
A process for preparing substantially pure trans-5-chloro-2-methyl-2,3,3a42b4etrahydro-lH-dibenz[2,3:6,
7]oxepino[4,5-c]pyrrole (Asenapine) of formula (I) is provided. The salts of intermediates useful for preparing Asenapine of formula ...
|
|
WO/2013/148324A1 |
Provided herein, inter alia, are anticancer polyketides. The uses of the polyketides described herein include treatment of cancer, for example, through regulation of the spliceosome and detection of spliceosome inhibition.
|
|
WO/2013/140752A1 |
A method for manufacturing 5-oxo-4-oxa-5-homoadmantane-2-ol expressed by the formula (I) by reacting 5-oxo-4-oxa-5-homoadmantane expressed by the formula (A) with hydrogen peroxide in the presence of sulfuric acid.
|
|
WO/2013/140969A1 |
The present invention is a photoresist composition which contains [A] a polymer that has a structural unit (I) containing an acid-cleavable group and a compound (I) that is represented by formula (1). In formula (1), each of R1, R2, R3 a...
|
|
WO/2013/116029A1 |
A process for synthesizing dodecane-1,12-diol, and by-products thereof, by the reduction of lauryl lactone produced from the oxidation of cyclododecanone.
|
|
WO/2013/072896A1 |
The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y-O-W (I), wherein Y and...
|
|
WO/2013/060818A1 |
Disclosed is a direct acid catalyzed intermolecular electrocyclic rearrangement process for the preparation of linear and cyclic homoallylic ester and amides.
|
|
WO/2013/061247A1 |
The present invention relates to a novel process for the preparation of trans-5-chloro-2- methyl-2,3,3a,12b- tetrahydro-1H-dibenz [2,3:6,7] oxepino[4,5-c] pyrrole (Asenapine) of formula (I). It also relates to novel intermediates i.e. 2-...
|
|
WO/2013/026942A1 |
The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity)...
|
|
WO/2013/013240A2 |
Compounds and compositions, which can be use for example, for treating cancer, are described herein.
|
|
WO/2013/000842A1 |
The invention relates to novel macrocyclic lactones, to methods for producing said macrocyclic lactones, to the use of said macrocyclic lactones as aromatic substances, and to products containing the novel macrocyclic lactones.
|
|
WO/2012/167171A2 |
The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.
|
|
WO/2012/140298A1 |
The invention relates to the use of yessotoxins and the derivatives thereof for producing a medicament for the prevention and/or treatment of metabolic diseases and preferably metabolic syndrome or diabetes mellitus type 2, inter alia.
|
|
WO/2012/115285A1 |
The present invention provides a novel macrocyclic compound exhibiting superior odor qualities and having a musk-like aroma, a method for producing the same, and a novel flavor or fragrance composition, and food products or beverages, fr...
|
|
WO/2012/107206A1 |
The present invention relates to the use of microcarpalide or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetener and/or a sweetness enhancer, to sweetener compositions comprising microcarpalide or a derivative o...
|
|
WO/2012/102357A1 |
The purpose of the present invention is to provide a compound having a potent and sustained activity of decreasing an intraocular pressure and having no adverse side effect on eyes. A compound represented by general formula (I) (wherein ...
|
|
WO/2012/070015A9 |
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...
|
|
WO/2012/078147A1 |
A process for preparing 4-[(2R)-2-X-methyl)-3-methylbutyl]-1 -methoxy-2-3(3- methoxypropoxy)-benzene wherein X is a leaving group and use of this compound in the synthesis of aliskiren.
|
|
WO/2012/060185A1 |
The present invention is a method for producing ester from ketone or aldehyde that is a reactant, using hydrogen peroxide by Baeyer-Villiger oxidation reaction, wherein as a catalyst, M(BAr4)n (M is an alkali metal or an alkali-earth met...
|
|
WO/2012/060397A1 |
Paroxetine, or a P2X4 receptor antagonist such as a diazepine dione derivative that is represented by general formula (IX) is used as a preventive or therapeutic agent for pain associated with herpes zoster in acute phase. (In the formul...
|
|
WO/2012/052843A1 |
The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharamceutical composition comprising the p...
|
|
WO/2012/038848A1 |
The invention relates to processes for preparing 1,6-hexanediol and very pure ε-caprolactone from a dicarboxylic acid solution (DCS), comprising the steps of (a) esterification of the DCS with alcohols, (b) partial catalytic hydrogenati...
|
|
WO/2012/027573A2 |
A shape-memory polymers comprising at least one monomer subunit represented by the following structural formula (1).
|
|
WO/2012/021974A1 |
The disclosure relates to resorcylic acid lactones and indolinone-containing compounds for use in treatment of diseases associated with aberrant protein processing, such as cystic fibrosis (CF; mucoviscidosis). The disclosure more genera...
|
|
WO/2012/020546A1 |
Compounds represented by formula (I) [wherein R1 is hydrogen, halogen, methyl, or trifluoromethyl].
|
|
WO/2012/013766A1 |
The present invention is directed to novel compounds of formula (I) as well as to the process for their preparation. Novel compounds of formula (I) can be converted into asenapine through an efficient process. The invention also relates ...
|
|
WO/2011/159551A1 |
Processes for making hydrogenated products including caprolactame (CL) caprolactone (CLO) or 1,6-hexanediol (HDO) and derivative thereof from monoammonium adipate (MAA) and/or adipic acid (AA) obtained from a clarified diammonium adipate...
|
|
WO/2011/159562A1 |
A process for making a hydrogenated product comprising caprolactone (CLO) and 1,6-hexanediol (HDO) and derivatives thereof from adipic acid (AA) obtained from fermentation broths containing diammonium adipate (DAA) or monoammonium adipat...
|
|
WO/2011/149339A1 |
The present invention relates to a method for preparing caprolactone, comprising converting 5-hydroxymethyl-2-furfuraldehyde by hydrogenation into at least one intermediate compound selected from the group of 2,5-tetrahydrofuran-dimethan...
|
|
WO/2011/128911A2 |
The present invention relates to an improved process for the preparation of 11- [(Z)-3-(dimethylamino)propylidene]-6, 11 -dihydrodibenzo[b,e]oxepin-2-aceticacid compound of formula- 1 and its pharmaceutically acceptable salts.
|
|
WO/2011/125291A1 |
Disclosed is a homoadamantane derivative represented by formula (I). In the formula, R1 and R2 each represent a hydrogen atom or C&1-6& linear, branched or cyclic hydrocarbon group; X represents a hydroxyl group or halogen atom; and n an...
|
|
WO/2011/110614A1 |
Disclosed are compounds of formula (I) wherein n is 1 or 2; and the dotted line together with carbon - carbon bond represents a single bond or a double bond. Furthermore, flavour and fragrance compositions comprising at least one compoun...
|
